Literature DB >> 25608166

Quantitative graphical analysis of simultaneous dynamic PET/MRI for assessment of prostate cancer.

Andrew B Rosenkrantz1, Thomas Koesters, Anne-Kristin Vahle, Kent Friedman, Rachel M Bartlett, Samir S Taneja, Yu-Shin Ding, Jean Logan.   

Abstract

PURPOSE: Dynamic FDG imaging for prostate cancer characterization is limited by generally small size and low uptake in prostate tumors. Our aim in this pilot study was to explore feasibility of simultaneous PET/MRI to guide localization of prostate lesions for dynamic FDG analysis using a graphical approach.
METHODS: Three patients with biopsy-proven prostate cancer underwent simultaneous FDG PET/MRI, incorporating dynamic prostate imaging. Histology and multiparametric MRI findings were used to localize tumors, which in turn guided identification of tumors on FDG images. Regions of interest were manually placed on tumor and benign prostate tissue. Blood activity was extracted from a region of interest placed on the femoral artery on PET images. FDG data were analyzed by graphical analysis using the influx constant Ki (Patlak analysis) when FDG binding seemed irreversible and distribution volume VT (reversible graphical analysis) when FDG binding seemed reversible given the presence of washout.
RESULTS: Given inherent coregistration, simultaneous acquisition facilitated use of MRI data to localize small lesions on PET and subsequent graphical analysis in all cases. In 2 cases with irreversible binding, tumor had higher Ki than benign using Patlak analysis (0.023 vs 0.006 and 0.019 vs 0.008 mL/cm3 per minute). In 1 case appearing reversible, tumor had higher VT than benign using reversible graphical analysis (0.68 vs 0.52 mL/cm3).
CONCLUSIONS: Simultaneous PET/MRI allows localization of small prostate tumors for dynamic PET analysis. By taking advantage of inclusion of the femoral arteries in the FOV, we applied advanced PET data analysis methods beyond conventional static measures and without blood sampling.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608166      PMCID: PMC4352122          DOI: 10.1097/RLU.0000000000000673

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  24 in total

1.  Dynamic contrast enhanced MRI of the prostate: comparison of gadobutrol and Gd-DTPA.

Authors:  T Durmus; B Vollnberg; C Schwenke; E Kilic; A Huppertz; M Taupitz; T Franiel
Journal:  Rofo       Date:  2013-07-25

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

3.  Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.

Authors:  Jan-Henning Schierz; Thomas Opfermann; Jörg Steenbeck; Eric Lopatta; Utz Settmacher; Andreas Stallmach; Robert J Marlowe; Martin Freesmeyer
Journal:  J Nucl Med       Date:  2013-03-25       Impact factor: 10.057

4.  Simultaneously acquired MR/PET images compared with sequential MR/PET and PET/CT: alignment quality.

Authors:  Cornelia B Brendle; Holger Schmidt; Sabrina Fleischer; Uli H Braeuning; Christina A Pfannenberg; Nina F Schwenzer
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

Review 5.  Whole body simultaneous PET/MRI: one-stop-shop?

Authors:  Nosheen Fatima; Zafar Sajjad; Unaiza Zaman
Journal:  J Pak Med Assoc       Date:  2014-02       Impact factor: 0.781

6.  Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.

Authors:  J-M Beauregard; S G Williams; T R Degrado; P Roselt; R J Hicks
Journal:  J Med Imaging Radiat Oncol       Date:  2010-08       Impact factor: 1.735

7.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

Review 8.  Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

9.  Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.

Authors:  Alexandr Kristian; Mona Elisabeth Revheim; Hong Qu; Gunhild M Mælandsmo; Olav Engebråten; Therese Seierstad; Eirik Malinen
Journal:  Acta Oncol       Date:  2013-08-29       Impact factor: 4.089

Review 10.  Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer.

Authors:  Seyed Saeid Dianat; H Ballentine Carter; Katarzyna J Macura
Journal:  Urol Oncol       Date:  2013-06-17       Impact factor: 3.498

View more
  3 in total

1.  18F-fluoro-2-deoxy-d-glucose (FDG) uptake. What are we looking at?

Authors:  Gianmario Sambuceti; Vanessa Cossu; Matteo Bauckneht; Silvia Morbelli; AnnaMaria Orengo; Sonia Carta; Silvia Ravera; Silvia Bruno; Cecilia Marini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05       Impact factor: 9.236

2.  Visualization of stress fractures of the foot using PET-MRI: a feasibility study.

Authors:  Moritz Crönlein; Isabel Rauscher; Ambros J Beer; Markus Schwaiger; Christoph Schäffeler; Marc Beirer; Stephan Huber; Gunther H Sandmann; Peter Biberthaler; Matthias Eiber; Chlodwig Kirchhoff
Journal:  Eur J Med Res       Date:  2015-12-23       Impact factor: 2.175

3.  Comparison of time curves from dynamic 18F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas.

Authors:  Andreas Julius Tulipan; Ljiljana Vlatkovic; Eirik Malinen; Bjørn Brennhovd; Knut Håkon Hole; Agnes Kathrine Lie; Harald Bull Ragnum; Mona-Elisabeth Revheim; Therese Seierstad
Journal:  Phys Imaging Radiat Oncol       Date:  2018-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.